{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:58:42Z","timestamp":1780444722873,"version":"3.54.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100013412","name":"Sanofi Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013412","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Axentiva Solutions"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-024-09637-x","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T02:03:12Z","timestamp":1722823392000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of twelve immunization-preventable infectious diseases on population health using disability-adjusted life years (DALYs) in Spain"],"prefix":"10.1186","volume":"24","author":[{"given":"Alberto","family":"P\u00e9rez-Rubio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Mestre-Ferrandiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luis","family":"L\u00f3pez-Belmonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Diaz-Aguil\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seila","family":"Lorenzo-Herrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"key":"9637_CR1","doi-asserted-by":"publisher","unstructured":"Baker RE, Mahmud AS, Miller IF et al. Infectious disease in an era of global change. Nature Reviews Microbiology 2021 20:4. 2021;20(4):193\u2013205. https:\/\/doi.org\/10.1038\/s41579-021-00639-z.","DOI":"10.1038\/s41579-021-00639-z"},{"issue":"9755","key":"9637_CR2","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/S0140-6736(10)61853-3","volume":"376","author":"A Alwan","year":"2010","unstructured":"Alwan A, MacLean DR, Riley LM, et al. Monitoring and surveillance of chronic non-communicable diseases: Progress and capacity in high-burden countries. Lancet. 2010;376(9755):1861\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(10)61853-3.","journal-title":"Lancet"},{"issue":"1 Suppl 1","key":"9637_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1590\/1678-4685-GMB-2020-0256","volume":"44","author":"JH Ellwanger","year":"2021","unstructured":"Ellwanger JH, da Veiga ABG, Kaminski VdeL, Valverde-Villegas JM, de Freitas AWQ, Chies JAB. Control and prevention of infectious diseases from a one health perspective. Genet Mol Biol. 2021;44(1 Suppl 1):1\u201323. https:\/\/doi.org\/10.1590\/1678-4685-GMB-2020-0256.","journal-title":"Genet Mol Biol"},{"key":"9637_CR4","doi-asserted-by":"publisher","unstructured":"Lo SW, Jamrozy D. Genomics and epidemiological surveillance. Nature Reviews Microbiology 2020 18:9. 2020;18(9):478\u2013478. https:\/\/doi.org\/10.1038\/s41579-020-0421-0.","DOI":"10.1038\/s41579-020-0421-0"},{"key":"9637_CR5","unstructured":"Roser M, Ritchie H, Spooner F. Burden of Disease. OurWorldInData.org. Published online 2021. Accessed March 3, 2023. https:\/\/ourworldindata.org\/burden-of-disease."},{"issue":"16","key":"9637_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2807\/1560-7917.ES.2018.23.16.17-00454\/CITE\/PLAINTEXT","volume":"23","author":"A Cassini","year":"2018","unstructured":"Cassini A, Colzani E, Pini A, et al. Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): results from the burden of communicable diseases in Europe study, European Union and European economic countries, 2009 to 2013. Eurosurveillance. 2018;23(16):17\u201300454. https:\/\/doi.org\/10.2807\/1560-7917.ES.2018.23.16.17-00454\/CITE\/PLAINTEXT.","journal-title":"Eurosurveillance"},{"key":"9637_CR7","doi-asserted-by":"publisher","unstructured":"Kuchenm\u00fcller T, Hird S, Stein C, Kramarz P, Nanda A, Havelaar AH. Estimating the global burden of foodborne diseases\u2013a collaborative effort. Euro Surveill. 2009;14(18). https:\/\/doi.org\/10.2807\/ESE.14.18.19195-EN.","DOI":"10.2807\/ESE.14.18.19195-EN"},{"issue":"10258","key":"9637_CR8","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"C Abbafati","year":"2020","unstructured":"Abbafati C, Abbas KM, Abbasi-Kangevari M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of Disease Study 2019. Lancet. 2020;396(10258):1204\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(20)30925-9.","journal-title":"Lancet"},{"issue":"4","key":"9637_CR9","doi-asserted-by":"publisher","first-page":"e1001205","DOI":"10.1371\/JOURNAL.PMED.1001205","volume":"9","author":"M Kretzschmar","year":"2012","unstructured":"Kretzschmar M, Mangen MJJ, Pinheiro P, et al. New Methodology for estimating the Burden of Infectious diseases in Europe. PLoS Med. 2012;9(4):e1001205. https:\/\/doi.org\/10.1371\/JOURNAL.PMED.1001205.","journal-title":"PLoS Med"},{"key":"9637_CR10","doi-asserted-by":"publisher","unstructured":"Mangen MJJ, Plass D, Havelaar AH, et al. The Pathogen- and incidence-based DALY Approach: an appropriated methodology for estimating the Burden of Infectious diseases. PLoS ONE. 2013;8(11). https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0079740.","DOI":"10.1371\/JOURNAL.PONE.0079740"},{"key":"9637_CR11","doi-asserted-by":"publisher","unstructured":"Colzani E, Cassini A, Lewandowski D, et al. A Software Tool for Estimation of Burden of Infectious diseases in Europe using incidence-based disability adjusted Life Years. PLoS ONE. 2017;12(1). https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0170662.","DOI":"10.1371\/JOURNAL.PONE.0170662"},{"issue":"9063","key":"9637_CR12","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/S0140-6736(96)07495-8","volume":"349","author":"CJL Murray","year":"1997","unstructured":"Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: global burden of Disease Study. Lancet. 1997;349(9063):1436\u201342. https:\/\/doi.org\/10.1016\/S0140-6736(96)07495-8.","journal-title":"Lancet"},{"key":"9637_CR13","unstructured":"Comisi\u00f3n de Salud P\u00fablica del Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad. Recomendaciones de Utilizaci\u00f3n de Nirsevimab Frente a Infecci\u00f3n Por Virus Respiratorio Sincitial de la Ponencia de Programa y Registro de Vacunaciones. 2023. Accessed March 3, 2023. https:\/\/www.sanidad.gob.es\/areas\/promocionPrevencion\/vacunaciones\/comoTrabajamos\/docs\/Nirsevimab.pdf."},{"key":"9637_CR14","unstructured":"Consejo, Interterritorial. Sistema Nacional de Salud. Calendario Com\u00fan de Vacunaci\u00f3n a Lo Largo de Toda La Vida. Calendario Recomendado A\u00f1o 2023.; 2023. Accessed February 14, 2023. https:\/\/www.sanidad.gob.es\/areas\/promocionPrevencion\/vacunaciones\/calendario-y-coberturas\/docs\/CalendarioVacunacion_Todalavida.pdf."},{"key":"9637_CR15","unstructured":"Spanish Statistical Office. Accessed February 1. 2023. https:\/\/www.ine.es\/en\/."},{"key":"9637_CR16","unstructured":"Burden of Disease toolkit - Application to calculate DALYs. Accessed February 1. 2023. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/toolkit-application-calculate-dalys."},{"key":"9637_CR17","unstructured":"Red Nacional de Vigilancia Epidemiol\u00f3gica. Resultados de la Vigilancia Epidemiol\u00f3gica de las enfermedades transmisibles. Informe anual. A\u00f1os 2017\u20132018. Published online 2018."},{"issue":"6","key":"9637_CR18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2213-2600(14)70034-7","volume":"2","author":"AC Hayward","year":"2014","unstructured":"Hayward AC, Fragaszy EB, Bermingham A, et al. Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. Lancet Respir Med. 2014;2(6):445\u201354. https:\/\/doi.org\/10.1016\/S2213-2600(14)70034-7.","journal-title":"Lancet Respir Med"},{"key":"9637_CR19","unstructured":"Sistema de Vigilancia de Infecci\u00f3n Respiratoria Aguda. Vigilancia Centinela de Infecci\u00f3n Respiratoria Aguda En Atenci\u00f3n Primaria (IRAs) y En Hospitales (IRAG) Gripe, COVID-19 y Otros Virus Respiratorios.; 2023."},{"key":"9637_CR20","unstructured":"Sistema d\u2019Informaci\u00f3 per a la Vigil\u00e0ncia d\u2019Infeccions a Catalunya. Accessed February 1. 2023. https:\/\/sivic.salut.gencat.cat\/."},{"key":"9637_CR21","unstructured":"Portal estad\u00edstico CMBD. Accessed February 1. 2023. https:\/\/pestadistico.inteligenciadegestion.sanidad.gob.es\/publicoSNS\/."},{"issue":"2","key":"9637_CR22","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1128\/CMR.00090-16","volume":"30","author":"CD Russell","year":"2017","unstructured":"Russell CD, Unger SA, Walton M, Schwarze J. The human Immune response to respiratory syncytial virus infection. Clin Microbiol Rev. 2017;30(2):481\u2013502. https:\/\/doi.org\/10.1128\/CMR.00090-16.","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"9637_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12889-020-09796-X\/FIGURES\/2","volume":"20","author":"JPS Villamil","year":"2020","unstructured":"Villamil JPS, Polack FP, Buend\u00eda JA. Disability-adjusted life years for respiratory syncytial virus in children under 2 years. BMC Public Health. 2020;20(1):1\u20135. https:\/\/doi.org\/10.1186\/S12889-020-09796-X\/FIGURES\/2.","journal-title":"BMC Public Health"},{"key":"9637_CR24","doi-asserted-by":"publisher","unstructured":"Nam HH, Ison MG. Respiratory syncytial virus infection in adults. BMJ. 2019;366. https:\/\/doi.org\/10.1136\/BMJ.L5021.","DOI":"10.1136\/BMJ.L5021"},{"key":"9637_CR25","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Reuni\u00f3n del Comit\u00e9 de Medicamentos de Uso Humano (CHMP) de septiembre 2022. Published 2022. Accessed March 3. 2023. https:\/\/www.aemps.gob.es\/informa\/reunion-del-comite-de-medicamentos-de-uso-humano-chmp-de-septiembre-2022\/."},{"key":"9637_CR26","doi-asserted-by":"publisher","unstructured":"Martin\u00f3n-Torres F, Carmo M, Platero L, et al. Clinical and economic burden of respiratory syncytial virus in Spanish children: the BARI study. BMC Infect Dis. 2022;22(1). https:\/\/doi.org\/10.1186\/S12879-022-07745-0.","DOI":"10.1186\/S12879-022-07745-0"},{"key":"9637_CR27","doi-asserted-by":"publisher","unstructured":"Martin\u00f3n-Torres F, Carmo M, Platero L, et al. Clinical and economic hospital burden of acute respiratory infection (BARI) due to respiratory syncytial virus in Spanish children, 2015\u20132018. BMC Infect Dis. 2023;23(1). https:\/\/doi.org\/10.1186\/S12879-023-08358-X.","DOI":"10.1186\/S12879-023-08358-X"},{"key":"9637_CR28","doi-asserted-by":"publisher","unstructured":"Heppe-Montero M, Gil-Prieto R, del Diego Salas J, Hern\u00e1ndez-Barrera V, Gil-de-Miguel \u00c1. Impact of respiratory syncytial virus and influenza virus infection in the Adult Population in Spain between 2012 and 2020. Int J Environ Res Public Health. 2022;19(22). https:\/\/doi.org\/10.3390\/IJERPH192214680.","DOI":"10.3390\/IJERPH192214680"},{"issue":"1","key":"9637_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/PAI.13131","volume":"31","author":"A Mejias","year":"2020","unstructured":"Mejias A, Wu B, Tandon N, et al. Risk of childhood wheeze and asthma after respiratory syncytial virus infection in full-term infants. Pediatr Allergy Immunol. 2020;31(1):47\u201356. https:\/\/doi.org\/10.1111\/PAI.13131.","journal-title":"Pediatr Allergy Immunol"},{"issue":"Supplement7","key":"9637_CR30","doi-asserted-by":"publisher","first-page":"S628","DOI":"10.1093\/INFDIS\/JIZ311","volume":"222","author":"T Shi","year":"2020","unstructured":"Shi T, Ooi Y, Zaw EM, et al. Association between Respiratory Syncytial Virus-Associated Acute Lower respiratory infection in early life and recurrent wheeze and asthma in later childhood. J Infect Dis. 2020;222(Supplement7):S628\u201333. https:\/\/doi.org\/10.1093\/INFDIS\/JIZ311.","journal-title":"J Infect Dis"},{"key":"9637_CR31","unstructured":"Emerson J, Kim DD. DALY Calculator.; 2018. Accessed February 1, 2024. https:\/\/cevr.shinyapps.io\/DALYcalculation\/."},{"issue":"Supplement4","key":"9637_CR32","doi-asserted-by":"publisher","first-page":"S380","DOI":"10.1093\/INFDIS\/JIAC390","volume":"226","author":"K Dooling","year":"2022","unstructured":"Dooling K, Marin M, Gershon AA. Clinical manifestations of Varicella: disease is largely forgotten, but it\u2019s not gone. J Infect Dis. 2022;226(Supplement4):S380\u20134. https:\/\/doi.org\/10.1093\/INFDIS\/JIAC390.","journal-title":"J Infect Dis"},{"key":"9637_CR33","doi-asserted-by":"publisher","unstructured":"Comit\u00e9 Asesor de Vacunas (CAV-AEP). Manual de Inmunizaciones en l\u00ednea de la AEP. Secci\u00f3n II. Cap\u00edtulo 7. Calendarios de inmunizaci\u00f3n en Espa\u00f1a. https:\/\/doi.org\/10.1016\/J.ANPEDI.2022.10.002.","DOI":"10.1016\/J.ANPEDI.2022.10.002"},{"key":"9637_CR34","doi-asserted-by":"publisher","unstructured":"Matthews S, De Maria A, Passamonti M, et al. The Economic Burden and Impact on Quality of life of herpes zoster and Postherpetic Neuralgia in individuals aged 50 years or older in Italy. Open Forum Infect Dis. 2019;6(2). https:\/\/doi.org\/10.1093\/OFID\/OFZ007.","DOI":"10.1093\/OFID\/OFZ007"},{"key":"9637_CR35","doi-asserted-by":"publisher","unstructured":"Patil A, Goldust M, Wollina U. Herpes zoster: a review of clinical manifestations and management. Viruses. 2022;14(2). https:\/\/doi.org\/10.3390\/V14020192.","DOI":"10.3390\/V14020192"},{"key":"9637_CR36","doi-asserted-by":"crossref","unstructured":"Redondo Fern\u00e1ndez M, Costillo Rodr\u00edguez J, Jim\u00e9nez Rodr\u00edguez M. Terap\u00e9utica en Atenci\u00f3n Primaria: Abordaje de la neuralgia postherp\u00e9tica en Atenci\u00f3n Primaria: situaci\u00f3n actual del tratamiento farmacol\u00f3gico. Semergen: revista espa\u00f1ola de medicina de familia, ISSN 1138\u20133593, No 2, 2007, p\u00e1gs 80\u201385. 2007;(2):80\u201385.","DOI":"10.1016\/S1138-3593(07)73853-4"},{"key":"9637_CR37","unstructured":"Red Nacional de Vigilancia Epidemiol\u00f3gica. Informe Epidemiol\u00f3gico Sobre La Situaci\u00f3n de Herpes Z\u00f3ster En Espa\u00f1a, 1998\u20132018.; 2020."},{"issue":"6","key":"9637_CR38","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3111\/13696998.2016.1146726","volume":"19","author":"JL Lopez-Belmonte","year":"2016","unstructured":"Lopez-Belmonte JL, Cisterna R, Demiguel A, Guilmet C, Biani F, Uhart M. The use of Zostavax in Spain: the economic case for vaccination of individuals aged 50 years and older. J Med Econ. 2016;19(6):576\u201386. https:\/\/doi.org\/10.3111\/13696998.2016.1146726.","journal-title":"J Med Econ"},{"key":"9637_CR39","doi-asserted-by":"publisher","unstructured":"Kwong JC, Ratnasingham S, Campitelli MA, et al. The impact of infection on population health: results of the Ontario burden of infectious diseases study. PLoS ONE. 2012;7(9). https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0044103.","DOI":"10.1371\/JOURNAL.PONE.0044103"},{"key":"9637_CR40","unstructured":"Clinical Overview of Herpes Zoster (Shingles) | CDC. Accessed February 21. 2023. https:\/\/www.cdc.gov\/shingles\/hcp\/clinical-overview.html."},{"issue":"1","key":"9637_CR41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/J.YAPD.2012.04.002","volume":"59","author":"PH Dennehy","year":"2012","unstructured":"Dennehy PH. Rotavirus infection: an update on management and prevention. Adv Pediatr. 2012;59(1):47\u201374. https:\/\/doi.org\/10.1016\/J.YAPD.2012.04.002.","journal-title":"Adv Pediatr"},{"key":"9637_CR42","unstructured":"Comisi\u00f3n de Salud P\u00fablica del Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad Consumo y Bienestar Social. Grupo de Trabajo Vacunaci\u00f3n En Prematuros de La Ponencia de Programa y Registro de Vacunaciones. Vacunaci\u00f3n En. 2019. Accessed June 2, 2023. https:\/\/www.sanidad.gob.es\/areas\/promocionPrevencion\/vacunaciones\/enfermedades\/docs\/Vacunacion_Prematuros.pdf."},{"issue":"1","key":"9637_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12963-015-0042-4\/TABLES\/3","volume":"13","author":"JA Haagsma","year":"2015","unstructured":"Haagsma JA, de Noordhout CM, Polinder S, et al. Assessing disability weights based on the responses of 30,660 people from four European countries. Popul Health Metr. 2015;13(1):1\u201315. https:\/\/doi.org\/10.1186\/S12963-015-0042-4\/TABLES\/3.","journal-title":"Popul Health Metr"},{"issue":"5","key":"9637_CR44","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1080\/14737167.2022.2020649","volume":"22","author":"J Rejas","year":"2022","unstructured":"Rejas J, Sicras-Mainar A, Sicras-Navarro A, Lwoff N, M\u00e9ndez C. All-cause community acquired pneumonia cost by age and risk in real-world conditions of care in Spain. Expert Rev Pharmacoecon Outcomes Res. 2022;22(5):853\u201367. https:\/\/doi.org\/10.1080\/14737167.2022.2020649.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"5","key":"9637_CR45","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/J.MEDCLE.2018.05.043","volume":"151","author":"JB Soriano","year":"2018","unstructured":"Soriano JB, Rojas-Rueda D, Alonso J, et al. The burden of disease in Spain: results from the global burden of Disease 2016. Med Cl\u00ednica (English Edition). 2018;151(5):171\u201390. https:\/\/doi.org\/10.1016\/J.MEDCLE.2018.05.043.","journal-title":"Med Cl\u00ednica (English Edition)"},{"issue":"3","key":"9637_CR46","doi-asserted-by":"publisher","first-page":"385","DOI":"10.23938\/ASSN.0962","volume":"44","author":"L Leache","year":"2021","unstructured":"Leache L, Guti\u00e9rrez-Valencia M, Saiz LC, Erviti J. Morbi-mortality of lower respiratory tract infections in Spain, 1997\u20132018. Sist Sanit Navar. 2021;44(3):385\u201396. https:\/\/doi.org\/10.23938\/ASSN.0962.","journal-title":"Sist Sanit Navar"},{"issue":"1","key":"9637_CR47","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3390\/ANTIBIOTICS12010172","volume":"12","author":"R Gil-Prieto","year":"2023","unstructured":"Gil-Prieto R, Allouch N, Jimeno I, Hern\u00e1ndez-Barrera V, Arguedas-Sanz R, Gil-de-Miguel \u00c1. Burden of hospitalizations related to pneumococcal infection in Spain (2016\u20132020). Antibiot (Basel). 2023;12(1):172. https:\/\/doi.org\/10.3390\/ANTIBIOTICS12010172.","journal-title":"Antibiot (Basel)"},{"key":"9637_CR48","doi-asserted-by":"publisher","unstructured":"de Gil \u00c1, Martin\u00f3n-Torres F, D\u00edez-Domingo J, et al. Clinical and economic burden of physician-diagnosed influenza in adults during the 2017\/2018 epidemic season in Spain. BMC Public Health. 2022;22(1). https:\/\/doi.org\/10.1186\/S12889-022-14732-2.","DOI":"10.1186\/S12889-022-14732-2"},{"issue":"10","key":"9637_CR49","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1017\/S0950268813003312","volume":"142","author":"D Plass","year":"2014","unstructured":"Plass D, Mangen MJJ, Kraemer A, et al. The disease burden of hepatitis B, influenza, measles and salmonellosis in Germany: first results of the Burden of Communicable diseases in Europe Study. Epidemiol Infect. 2014;142(10):2024\u201335. https:\/\/doi.org\/10.1017\/S0950268813003312.","journal-title":"Epidemiol Infect"},{"issue":"4","key":"9637_CR50","doi-asserted-by":"publisher","first-page":"e0153106","DOI":"10.1371\/JOURNAL.PONE.0153106","volume":"11","author":"A Van Lier","year":"2016","unstructured":"Van Lier A, McDonald SA, Bouwknegt M, et al. Disease Burden of 32 infectious diseases in the Netherlands, 2007\u20132011. PLoS ONE. 2016;11(4):e0153106. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0153106.","journal-title":"PLoS ONE"},{"key":"9637_CR51","unstructured":"Centro Nacional de Epidemiolog\u00eda, Instituto de Salud Carlos III. Informe de Vigilancia de La Gripe En Espa\u00f1a. Temporada 2019\u20132020. 2020. Accessed February 15, 2023. http:\/\/vgripe.isciii.es\/."},{"key":"9637_CR52","unstructured":"Ministerio de Sanidad. Sistema de Informaci\u00f3n de Vacunaciones (SIVAMIN). Portal estad\u00edstico. \u00c1rea de Inteligencia de Gesti\u00f3n. Accessed February 15. 2023. https:\/\/pestadistico.inteligenciadegestion.sanidad.gob.es\/publicoSNS\/S\/sivamin."},{"key":"9637_CR53","doi-asserted-by":"publisher","unstructured":"European Centre for Disease Prevention and Control. Seasonal Influenza Vaccination Recommendations and Coverage Rates in EU\/EEA Member States. 2023. https:\/\/doi.org\/10.2900\/335933.","DOI":"10.2900\/335933"},{"key":"9637_CR54","unstructured":"Council of the European Union. Council recommendation of 7 December 2018 on strengthened cooperation against vaccine-preventable diseases (2018\/C 466\/01). Oficial Journal of the European Union. Published online 2018."},{"key":"9637_CR55","unstructured":"European Centre for Disease Prevention and Control. Seasonal Influenza Vaccination and Antiviral Use in EU\/EEA Member States. 2018. Accessed February 15, 2023. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/seasonal-influenza-vaccination-antiviral-use-eu-eea-member-states."},{"issue":"7","key":"9637_CR56","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMOA1315727","volume":"371","author":"CA DiazGranados","year":"2014","unstructured":"DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635\u201345. https:\/\/doi.org\/10.1056\/NEJMOA1315727.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"9637_CR57","doi-asserted-by":"publisher","first-page":"A24","DOI":"10.1016\/J.VACCINE.2020.09.004","volume":"39","author":"JKH Lee","year":"2021","unstructured":"Lee JKH, Lam GKL, Shin T, Samson SI, Greenberg DP, Chit A. Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: an updated systematic review and meta-analysis. Vaccine. 2021;39(Suppl 1):A24\u201335. https:\/\/doi.org\/10.1016\/J.VACCINE.2020.09.004.","journal-title":"Vaccine"},{"issue":"39","key":"9637_CR58","doi-asserted-by":"publisher","first-page":"5825","DOI":"10.1016\/J.VACCINE.2019.08.016","volume":"37","author":"LJ Chang","year":"2019","unstructured":"Chang LJ, Meng Y, Janosczyk H, Landolfi V, Talbot HK. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults\u2009\u2265\u200965 years of age: a phase 3 randomized clinical trial. Vaccine. 2019;37(39):5825\u201334. https:\/\/doi.org\/10.1016\/J.VACCINE.2019.08.016.","journal-title":"Vaccine"},{"issue":"4","key":"9637_CR59","doi-asserted-by":"publisher","first-page":"226","DOI":"10.37201\/REQ\/043.2020","volume":"33","author":"\u00c1G de Miguel","year":"2020","unstructured":"de Miguel \u00c1G, Marguello ER, Domingo JD, de Lejarazu RO, Torres FM. [High-dose trivalent influenza vaccine. Efficacy and effectiveness]. Rev Esp Quimioter. 2020;33(4):226\u201339. https:\/\/doi.org\/10.37201\/REQ\/043.2020.","journal-title":"Rev Esp Quimioter"},{"key":"9637_CR60","unstructured":"Sociedad Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda. Recomendaciones de Vacunaci\u00f3n Para Adultos y Mayores 2022\u20132023. 2022. Accessed June 29, 2023. https:\/\/www.segg.es\/media\/descargas\/Recomendaciones-de-vacunacion-2022-2023.pdf."},{"key":"9637_CR61","doi-asserted-by":"publisher","unstructured":"Heppe Montero M, Gil-Prieto R, Walter S, Aleixandre Blanquer F, De Gil \u00c1. Burden of severe bronchiolitis in children up to 2 years of age in Spain from 2012 to 2017. Hum Vaccin Immunother. 2022;18(1). https:\/\/doi.org\/10.1080\/21645515.2021.1883379.","DOI":"10.1080\/21645515.2021.1883379"},{"key":"9637_CR62","doi-asserted-by":"publisher","unstructured":"Gea-Izquierdo E, Gil-Prieto R, Hern\u00e1ndez-Barrera V, Gil-de-Miguel \u00c1. Respiratory syncytial virus-associated hospitalization in children aged\u2009<\u20092 years in Spain from 2018 to 2021. Hum Vaccin Immunother. 2023;19(2). https:\/\/doi.org\/10.1080\/21645515.2023.2231818.","DOI":"10.1080\/21645515.2023.2231818"},{"issue":"16","key":"9637_CR63","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1016\/J.VACCINE.2023.03.024","volume":"41","author":"Z Mao","year":"2023","unstructured":"Mao Z, Li X, Dacosta-Urbieta A, et al. Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: a multi-country prospective cohort study in Europe. Vaccine. 2023;41(16):2707\u201315. https:\/\/doi.org\/10.1016\/J.VACCINE.2023.03.024.","journal-title":"Vaccine"},{"issue":"4","key":"9637_CR64","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/S41669-022-00329-3","volume":"6","author":"\u00c1 de Gil","year":"2022","unstructured":"de Gil \u00c1, Eiros Bouza JM, Mart\u00ednez Alcorta LI, et al. Direct Medical costs of four vaccine-preventable infectious diseases in older adults in Spain. Pharmacoecon Open. 2022;6(4):509. https:\/\/doi.org\/10.1007\/S41669-022-00329-3.","journal-title":"Pharmacoecon Open"},{"issue":"7","key":"9637_CR65","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/J.VACCINE.2015.12.052","volume":"34","author":"M Kristensen","year":"2016","unstructured":"Kristensen M, Van Lier A, Eilers R, et al. Burden of four vaccine preventable diseases in older adults. Vaccine. 2016;34(7):942\u20139. https:\/\/doi.org\/10.1016\/J.VACCINE.2015.12.052.","journal-title":"Vaccine"},{"issue":"10340","key":"9637_CR66","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","volume":"399","author":"Y Li","year":"2022","unstructured":"Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(22)00478-0.","journal-title":"Lancet"},{"issue":"3","key":"9637_CR67","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/S40121-016-0123-0","volume":"5","author":"L Bont","year":"2016","unstructured":"Bont L, Checchia PA, Fauroux B, et al. Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in Western Countries. Infect Dis Ther. 2016;5(3):271\u201398. https:\/\/doi.org\/10.1007\/S40121-016-0123-0.","journal-title":"Infect Dis Ther"},{"issue":"2","key":"9637_CR68","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/IRV.12937","volume":"16","author":"A Mira-Iglesias","year":"2022","unstructured":"Mira-Iglesias A, Demont C, L\u00f3pez-Labrador FX, et al. Role of age and birth month in infants hospitalized with RSV-confirmed disease in the Valencia Region, Spain. Influenza Other Respir Viruses. 2022;16(2):328\u201339. https:\/\/doi.org\/10.1111\/IRV.12937.","journal-title":"Influenza Other Respir Viruses"},{"issue":"3","key":"9637_CR69","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/INF.0000000000000993","volume":"35","author":"C Mu\u00f1oz-Quiles","year":"2016","unstructured":"Mu\u00f1oz-Quiles C, L\u00f3pez-Lacort M, \u00dabeda-Sansano I, et al. Population-based Analysis of Bronchiolitis Epidemiology in Valencia, Spain. Pediatr Infect Dis J. 2016;35(3):275\u201380. https:\/\/doi.org\/10.1097\/INF.0000000000000993.","journal-title":"Pediatr Infect Dis J"},{"key":"9637_CR70","doi-asserted-by":"publisher","unstructured":"Viguria N, Mart\u00ednez-Baz I, Moreno-Galarraga L, Sierrases\u00famaga L, Salcedo B, Castilla J. Respiratory syncytial virus hospitalization in children in northern Spain. PLoS ONE. 2018;13(11). https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0206474.","DOI":"10.1371\/JOURNAL.PONE.0206474"},{"issue":"5","key":"9637_CR71","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/J.GACETA.2018.11.009","volume":"34","author":"M Servia-Dopazo","year":"2020","unstructured":"Servia-Dopazo M, Purri\u00f1os-Hermida MJ, P\u00e9rez S, et al. [Usefulness of the microbiological surveillance of respiratory syncytial virus in Galicia (Spain): 2008\u20132017]. Gac Sanit. 2020;34(5):474\u20139. https:\/\/doi.org\/10.1016\/J.GACETA.2018.11.009.","journal-title":"Gac Sanit"},{"issue":"1","key":"9637_CR72","first-page":"58e","volume":"98","author":"FJ \u00c1lvarez Garc\u00eda","year":"2023","unstructured":"\u00c1lvarez Garc\u00eda FJ, Cilleruelo Ortega MJ, \u00c1lvarez Alde\u00e1n J, et al. Calendario De inmunizaciones de la Asociaci\u00f3n Espa\u00f1ola De Pediatr\u00eda: recomendaciones 2023. Pediatr (Engl Ed). 2023;98(1):58e. 1-58.e10.","journal-title":"Pediatr (Engl Ed)"},{"issue":"3","key":"9637_CR73","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S2352-4642(22)00321-2","volume":"7","author":"EAF Sim\u00f5es","year":"2023","unstructured":"Sim\u00f5es EAF, Madhi SA, Muller WJ, et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023;7(3):180\u20139. https:\/\/doi.org\/10.1016\/S2352-4642(22)00321-2.","journal-title":"Lancet Child Adolesc Health"},{"key":"9637_CR74","unstructured":"SIVIC - VRS, Accessed. January 19, 2023. https:\/\/sivic.salut.gencat.cat\/vrs?ftemporada=13."},{"key":"9637_CR75","unstructured":"Virus Sincitial Respiratorio - Conseller\u00eda de Sanidade - Servizo Galego de Sa\u00fade. Accessed March 19. 2023. https:\/\/www.sergas.es\/Saude-publica\/Virus-Sincitial-Respiratorio?idioma=es."},{"issue":"1","key":"9637_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12913-023-10071-Z\/METRICS","volume":"23","author":"S den Boon","year":"2023","unstructured":"den Boon S, Ahmed S, Sarker AR. Economic evaluations of immunization programs as an indispensable tool for policymakers. BMC Health Serv Res. 2023;23(1):1\u20133. https:\/\/doi.org\/10.1186\/S12913-023-10071-Z\/METRICS.","journal-title":"BMC Health Serv Res"},{"key":"9637_CR77","unstructured":"Plataforma de Contrataci\u00f3n del Sector P\u00fablico. Accessed February 20. 2023. https:\/\/contrataciondelestado.es\/wps\/portal\/plataforma."},{"key":"9637_CR78","unstructured":"Sistema Nacional de Salud. Calendario Com\u00fan de Vacunaci\u00f3n a Lo Largo de Toda La Vida. 2022. https:\/\/www.sanidad.gob.es\/areas\/promocionPrevencion\/vacunaciones\/calendario-y-coberturas\/calendario\/docs\/CalendarioVacunacion_Todalavida_2022.pdf."},{"issue":"1","key":"9637_CR79","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/S12879-023-08015-3","volume":"23","author":"T Pumarola","year":"2023","unstructured":"Pumarola T, D\u00edez-Domingo J, Martin\u00f3n-Torres F, et al. Excess hospitalizations and mortality associated with seasonal influenza in Spain, 2008\u20132018. BMC Infect Dis. 2023;23(1):86. https:\/\/doi.org\/10.1186\/S12879-023-08015-3.","journal-title":"BMC Infect Dis"},{"key":"9637_CR80","doi-asserted-by":"publisher","unstructured":"Vall\u00e9e A. Underestimation of the number of COVID-19 cases, an epidemiological threat. Epidemiol Infect. 2022;150. https:\/\/doi.org\/10.1017\/S0950268822001728.","DOI":"10.1017\/S0950268822001728"},{"issue":"1","key":"9637_CR81","doi-asserted-by":"publisher","first-page":"E19","DOI":"10.1503\/CMAJ.1096031","volume":"195","author":"D Duong","year":"2023","unstructured":"Duong D. What RSV interventions are in the research pipeline? CMAJ. 2023;195(1):E19\u201320. https:\/\/doi.org\/10.1503\/CMAJ.1096031.","journal-title":"CMAJ"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09637-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-09637-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09637-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T02:04:43Z","timestamp":1722823483000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-09637-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9637"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-09637-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3621222\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,5]]},"assertion":[{"value":"16 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AD and JLLB are employees of Sanofi and may hold shares and\/or stock options in the company. SLH and CC are consultants of Axentiva Solutions, which received consultancy fees from Sanofi, Spain and, during the conduct of this study, from other pharmaceutical companies in unrelated projects. JMF reports having received a consulting fee from Axentiva Solutions for collaboration in this study and, during the conduct of this study, from other Sanofi funded projects related to RSV. AP reports having received funding from Sanofi for collaboration in this study and, during the conduct of this study, from other pharmaceutical companies in unrelated projects.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"779"}}